Cobimetinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Melanoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • Histiocytic Neoplasms COTELLIC®, as a single agent, is indicated for the treatment of adult patients with histiocytic neoplasms.
Product first approved 2015Outside this platform's coverageFDA label
EU
  • Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Product first approved 2015EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Melanoma
NCT03273153 · Hoffmann-La Roche
2017-12-11 – 2021-02-19 · Advanced BRAFV600 Wild-type Melanoma
What this study did
NCT02427893 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2015-08 – 2016-11 · Melanoma
What this study did
Other / comorbidity
NCT03768063 · Hoffmann-La Roche
2019-02-28 – 2028-07-05 · Cancer
What this study did
NCT04007848 · Assistance Publique - Hôpitaux de Paris
2019-07-25 – 2022-03-14 · Disease or R Group Histiocytoses
What this study did
Phase 2/3 (3)
Melanoma
NCT05768178 · Cancer Research UK
2023-03-01 – 2029-10 · Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic, Solid Tumour
What this study did
Other / comorbidity
NCT05722886 · Cancer Research UK
2023-03-01 – 2029-10 · Haematological Malignancy, Solid Tumour
What this study did
NCT03178552 · Hoffmann-La Roche
2017-09-22 – 2027-06-30 · Non-Small Cell Lung Cancer
What this study did
Phase 2 (52)
Melanoma
NCT07449754 · Hanmi Pharmaceutical Company Limited
2026-02-12 – 2030-03 · Advanced or Metastatic Melanoma
What this study did
NCT03175432 · M.D. Anderson Cancer Center
2017-06-15 – 2028-06-30 · BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Refractory Melanoma
What this study did
NCT04722575 · Fondazione Melanoma Onlus
2020-12-03 – 2027-06 · Melanoma
What this study did
NCT05756556 · ImmVira Pharma Co. Ltd
2024-06-30 – 2027-01-01 · Melanoma, Malignant Melanoma
What this study did
NCT03554083 · Mayo Clinic
2018-10-05 – 2025-04-30 · Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
What this study did
NCT02036086 · Sunnybrook Health Sciences Centre
2015-08 – 2024-01-31 · Melanoma
What this study did
NCT02968303 · Radboud University Medical Center
2017-01-27 – 2023-10 · Melanoma, Malignant, of Soft Parts
What this study did
NCT03430947 · Technische Universität Dresden
2018-07-01 – 2023-02-10 · Malignant Melanoma Stage IV, BRAF V600 Mutation, Brain Metastases
What this study did
NCT03224208 · Fondazione Melanoma Onlus
2018-05-17 – 2021-01-08 · Melanoma, Melanoma (Skin), Melanoma Stage
What this study did
NCT02414750 · Netherlands Working Group on Immunotherapy of Oncology
2014-12 – 2020-11 · Metastatic Melanoma
What this study did
NCT02303951 · University Hospital Tuebingen
2015-01-22 – 2020-05-14 · Malignant Melanoma
What this study did
NCT02537600 · Center Eugene Marquis
2015-12 – 2019-11-06 · Malignant Melanoma
What this study did
NCT03005639 · Inova Health Care Services
2017-06-01 – 2018-02-24 · Stage IIIB-C Melanoma
What this study did
NCT01813214 · Georgetown University
2013-03 – 2016-12 · Melanoma
What this study did
NCT01495988 · Melanoma Research Foundation Breakthrough Consortium
2013-08 – 2016-06 · Melanoma, Metastatic Melanoma
What this study did
NCT02230306 · Melissa Burgess, MD
2015-02 – 2016-03 · Active Melanoma Brain Metastases
What this study did
Other / comorbidity
NCT05159245 · Helsinki University Central Hospital
2021-12-10 – 2032-11-25 · Advanced Cancer, Solid Tumor, Haematological Malignancy
What this study did
NCT04302025 · Genentech, Inc.
2020-11-06 – 2030-05-30 · Non-small Cell Lung Cancer
What this study did
NCT04341181 · Ulrik Lassen
2020-08-24 – 2030-04-30 · Cancer, Tumors, Neoplasms, Neoplasia
What this study did
NCT04079179 · Carl Allen
2021-04-19 – 2029-12 · Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
What this study did
NCT02693535 · American Society of Clinical Oncology
2016-03-14 – 2028-12-31 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT03224767 · Alliance for Clinical Trials in Oncology
2018-01-05 – 2028-08-01 · BRAF V600E Mutation Present, Papillary Craniopharyngioma
What this study did
NCT04931342 · Hoffmann-La Roche
2021-10-07 – 2028-05-30 · Ovarian Cancer
What this study did
NCT06813079 · University Health Network, Toronto
2025-04-07 – 2028-02-17 · Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor
What this study did
NCT03202316 · M.D. Anderson Cancer Center
2017-08-11 – 2027-12-31 · Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
What this study did
NCT02925234 · The Netherlands Cancer Institute
2016-08 – 2027-12 · Cancer, Tumors, Neoplasm, Neoplasia
What this study did
NCT03600701 · National Cancer Institute (NCI)
2018-11-29 – 2027-10-03 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT03181100 · M.D. Anderson Cancer Center
2017-07-27 – 2027-07-31 · Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Carcinoma
What this study did
NCT03297606 · Canadian Cancer Trials Group
2018-03-23 – 2027-01-31 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT06440850 · City of Hope Medical Center
2024-07-15 – 2026-11-22 · Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
What this study did
NCT04409639 · University of Utah
2021-01-12 – 2026-10 · Chronic Myelomonocytic Leukemia (CMML)
What this study did
NCT04941287 · National Cancer Institute (NCI)
2021-12-15 – 2026-04-29 · Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma
What this study did
NCT03363867 · Peter MacCallum Cancer Centre, Australia
2018-07-10 – 2026-02-12 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT05125471 · University of Arkansas
2022-07-26 – 2025-09-03 · Arteriovenous Malformations (Extracranial)
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
NCT03340558 · Niharika Mettu
2018-05 – 2025-02 · Metastatic Colorectal Cancer
What this study did
NCT04551521 · German Cancer Research Center
2021-10-13 – 2024-12-30 · Metastatic or Locally Advanced Malignancies
What this study did
NCT02060188 · Bristol-Myers Squibb
2014-03-12 – 2024-10-22 · Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
What this study did
NCT04185831 · Uppsala University Hospital
2020-10-20 – 2024-10 · Solid Tumor
What this study did
NCT03108131 · M.D. Anderson Cancer Center
2017-04-07 – 2024-04-02 · Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Malignant Neoplasm, Metastatic Skin Squamous Cell Carcinoma, Metastatic Small Intestinal Adenocarcinoma, Rare Neoplastic Syndrome, Refractory Malignant Neoplasm, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Unresectable Malignant Neoplasm
What this study did
NCT03201458 · National Cancer Institute (NCI)
2018-02-08 – 2024-02-19 · Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma
What this study did
NCT03395899 · Queen Mary University of London
2017-12-21 – 2023-08-18 · Breast Cancer, Estrogen Receptor-positive Breast Cancer
What this study did
NCT02091141 · Genentech, Inc.
2014-04-14 – 2023-05-24 · Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
What this study did
NCT02649972 · Memorial Sloan Kettering Cancer Center
2016-01 – 2022-12-16 · Histiocytic Disorders
What this study did
Phase 1/2 (14)
Melanoma
NCT03101254 · Dana-Farber Cancer Institute
2017-06-06 – 2020-11-11 · Melanoma
What this study did
NCT01959633 · Fondazione Melanoma Onlus
2014-04-03 – 2018-03-26 · Melanoma
What this study did
Other / comorbidity
NCT03202940 · Massachusetts General Hospital
2017-09-14 – 2031-01-01 · Non-small Cell Lung Cancer
What this study did
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03281369 · Hoffmann-La Roche
2017-10-13 – 2025-10-09 · Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
What this study did
NCT04216953 · Centre Leon Berard
2020-02-12 – 2025-03-17 · Sarcoma,Soft Tissue
What this study did
NCT03193190 · Hoffmann-La Roche
2017-07-05 – 2025-02-27 · Pancreatic Adenocarcinoma
What this study did
NCT03732703 · Multiple Myeloma Research Consortium
2019-04-01 – 2024-12-31 · Relapsed Refractory Multiple Myeloma
What this study did
NCT01928394 · Bristol-Myers Squibb
2013-10-24 – 2024-11-18 · Advanced or Metastatic Solid Tumors
What this study did
NCT03989115 · Revolution Medicines, Inc.
2019-07-02 – 2022-02-08 · Solid Tumor
What this study did
NCT02639546 · Hoffmann-La Roche
2016-05-20 – 2021-07-21 · Solid Tumors
What this study did
NCT03566485 · Vanderbilt-Ingram Cancer Center
2018-07-10 – 2020-12-10 · Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Estrogen Receptor-positive, HER2/Neu Negative
What this study did
Phase 1 (33)
Melanoma
NCT02721459 · H. Lee Moffitt Cancer Center and Research Institute
2016-09-07 – 2026-11-04 · Melanoma, Skin Cancer
What this study did
NCT04109456 · InxMed (Shanghai) Co., Ltd.
2020-03-16 – 2024-12-20 · Metastatic Melanoma
What this study did
NCT02818023 · Yana Najjar
2016-07-13 – 2021-04-23 · Melanoma
What this study did
NCT01876641 · Mohammed M Milhem
2013-10 – 2018-09 · Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
What this study did
NCT01271803 · Hoffmann-La Roche
2011-02-17 – 2017-12-12 · Malignant Melanoma
What this study did
NCT02457793 · Genentech, Inc.
2015-06-16 – 2016-12-05 · Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
What this study did
Other / comorbidity
NCT04005690 · OHSU Knight Cancer Institute
2019-08-01 – 2028-02-01 · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
What this study did
NCT05691504 · National Cancer Institute (NCI)
2023-09-14 – 2027-02-01 · Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
What this study did
NCT05034627 · OHSU Knight Cancer Institute
2022-08-09 – 2026-06-03 · Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT05441514 · City of Hope Medical Center
2023-04-28 – 2026-03-19 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03284502 · Hanmi Pharmaceutical Company Limited
2017-05-22 – 2024-12-31 · Locally Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT04190628 · ABM Therapeutics Corporation
2020-06-16 – 2024-04-05 · Advanced Solid Tumor, BRAF V600 Mutation
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT01988896 · Hoffmann-La Roche
2013-12-27 – 2019-11-04 · Solid Tumors
What this study did
NCT02876224 · Hoffmann-La Roche
2016-09-30 – 2019-06-25 · Colorectal Cancer
What this study did
NCT01986166 · Genentech, Inc.
2013-11 – 2016-01 · Neoplasms
What this study did
NCT02300025 · Genentech, Inc.
2014-08 – 2015-01 · Healthy Volunteer
What this study did
NCT01974258 · Hoffmann-La Roche
2014-02 – 2014-07 · Neoplasms
What this study did
NCT00467779 · Genentech, Inc.
2007-05 – 2014-04 · Solid Tumor
What this study did
NCT01929876 · Genentech, Inc.
2013-07 – 2013-10 · Healthy Participants
What this study did
NCT01711762 · Genentech, Inc.
2012-09 – 2012-09 · Healthy Volunteer
What this study did
NCT01277718 · Genentech, Inc.
2011-01 – 2011-02 · Healthy Volunteer
What this study did
NCT01249131 · Genentech, Inc.
2010-12-01 – 2011-01-10 · Healthy Volunteers
What this study did
NCT01249118 · Genentech, Inc.
2010-11 – 2011-01 · Healthy Volunteers
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Melanoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cobimetinib: this drugApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Luvometinib
Phase 3(overall)
Small moleculeMEK1/2
not yet graded(overall)
No reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cobimetinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (2)
Phase 2Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary CarcinomaRecruiting
Est. primary completion 2026-11-22 · NCT06440850 · CT.gov ↗
What to watch
Phase 2Non-small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT04302025 · CT.gov ↗
What to watch
December 2026 (2)
Phase 1MelanomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04835805 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
2027 (7)
February 2027 (1)
Phase 1Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma …Active not recruiting
Est. primary completion 2027-02-01 · NCT05691504 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2027-06-01 · NCT04005690 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8 …Active not recruiting
Est. primary completion 2027-07-31 · NCT03181100 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03202316 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 2Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease …Recruiting
Est. primary completion 2028-01 · NCT04079179 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial TumorRecruiting
Est. primary completion 2028-02-17 · NCT06813079 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2028-06-30 · NCT03175432 · CT.gov ↗
What to watch
July 2028 (1)
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
2029 (5)
January 2029 (1)
Phase 1/2Non-small Cell Lung CancerActive not recruiting
Est. primary completion 2029-01-01 · NCT03202940 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2029-09 · NCT07449754 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2/3MelanomaRecruiting
Est. primary completion 2029-10 · NCT05768178 · CT.gov ↗
What to watch
Phase 2/3Haematological Malignancy, Solid TumourRecruiting
Est. primary completion 2029-10 · NCT05722886 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2031-11-25 · NCT05159245 · CT.gov ↗
What to watch

See the full readout calendar ↗